Company profile

Tasly Pharmaceutical Group

Traditional Chinese medicine, cardiovascular franchise

600535 · SSE · China

Public Market Listing

600535SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Tasly Pharmaceutical Group are available on Yahoo Finance.

External market data link · No third-party exchange redistribution

Assets

(4 total)

4Total Assets

0Approved

0Phase 3 / Filed

4Phase 1–2 / Early

2Diseases

Showing 4 of 4 assets

		Target & Modality
B1962	Phase 2	PD-L1 / VEGFMultispecific antibody	Non-Small Cell Lung Cancer
Jia Shen Tablet	Phase 2	Multi-target (ginsenoside)Botanical	Heart Failure
QiShenYiQi	Phase 2	Multi-target (ginsenoside)Botanical	Heart Failure
HucMSC intramyocardial therapy	Phase 1/2	Cardiac cell therapyCell therapy	Heart Failure

Research

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Research

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.